As if there weren't enough reasons to buy shares of the cardiometabolic drug juggernauts Eli Lilly (LLY 0.74%) and Novo Nordisk (NVO -0.28%), there's now one more big reason to ex ...
Plus, with a pipeline that includes blockbuster drugs like Ozempic and Wegovy, NovoNordisk is making moves in the cardiovascular space, and even eyeing treatments for Alzheimer's and alcohol ...
Results that may be inaccessible to you are currently showing.